TY  - JOUR
TI  - MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS
AB  - Objective: Colon cancer is the third most common cancer type globally and usually occurs at advanced ages. Since the risk of comorbid diseases may also increase with age, colon cancer patients have an increased risk of polypharmacy. Hypertension, chronic obstructive pulmonary disease, diabetes, and cardiovascular disease are the frequently seen comorbidities in cancer patients. Patients who are elderly, have comorbid conditions, and are taking two or more medications are at higher risk for drug-drug interactions (DDIs). Additionally, cancer patients frequently use many drugs such as supportive care drugs for the treatment of side effects of cytotoxic drugs. DDIs may cause therapeutic failure or potentially serious adverse events. determination and evaluation of DDI levels identify the most suitable rational therapy for cancer patients. Result and Discussion: This study has reviewed the drugs used to treat colon cancer (Capecitabine, Fluorouracil, Irinotecan, Oxaliplatin, Bevacizumab, Ziv-Aflibercept, Nivolumab, Pembrolizumab, Ramucirumab, Regorafenib, Larotrectinib, Dabrafenib, Trametinib, Trifluridine and tipiracil, and Encorafenib) and determined the possible drug-drug interactions. This study will help the pharmacists and clinicians to evaluate possible interactions.
AU  - tezcan, songül
DO  - 10.33483/jfpau.1039307
PY  - 2022
JO  - Ankara Üniversitesi Eczacılık Fakültesi Dergisi
VL  - 46
IS  - 2
SN  - 1015-3918
SP  - 537
EP  - 550
DB  - TRDizin
UR  - http://search/yayin/detay/1118973
ER  -